| (Values in U.S. Thousands) | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 |
| Sales | 0 | 0 | 80 | 280 | 0 |
| Sales Growth | unch | -100.00% | -71.43% | unch | -100.00% |
| Net Income | -2,080 | -2,430 | -530 | 410 | -5,940 |
| Net Income Growth | +14.40% | -358.49% | -229.27% | +106.90% | +12.26% |
Peak Bio Inc (PKBO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Peak Bio Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing significant unmet needs in the areas of oncology and inflammation. The company's lead product candidate includes PHP-303. Peak Bio Co., Ltd., formerly known as Ignyte Acquisition Corp., is based in NEW YORK.
Fiscal Year End Date: 12/31